• Explore /
  • Poster
  • / A novel humanized anti-CTLA-4 antibody compared to ipilimumab in preclinical studies.

A novel humanized anti-CTLA-4 antibody compared to ipilimumab in preclinical studies.

Abstract Poster

Authors

null

Qian Shi

CBT Pharmaceuticals, Pleasanton, CA

Qian Shi, YanLi Liu, Lan Yang, Hongli Ma, Wencui Ma, Ziyong Sun

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO-SITC Clinical Immuno-Oncology Symposium

Session Type

Poster Session

Session Title

Poster Session A

Track

Breast and Gynecologic Cancers,Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Hematologic Malignancies

Sub Track

Immune Checkpoints and Stimulatory Receptors

Citation

J Clin Oncol 37, 2019 (suppl 8; abstr 32)

DOI

10.1200/JCO.2019.37.8_suppl.32

Abstract #

32

Poster Bd #

C1

Abstract Disclosures

Similar Posters

First Author: Guillermo De Velasco

First Author: Anna Maria Di Giacomo

First Author: Mark Selby

First Author: Maria Jure-Kunkel